Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

por Abbas, Hussein A., Wierda, William G.
Publicado 2021

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

por Tambaro, Francesco Paolo, De Novellis, Danilo, Wierda, William G
Publicado 2021

Regulation of Mcl-1 Expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia()

por Balakrishnan, Kumudha, Burger, Jan A., Fu, Min, Doifode, Tejaswini, Wierda, William G., Gandhi, Varsha
Publicado 2014

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic

por Balakrishnan, Kumudha, Fu, Min, Onida, Francesco, Wierda, William G., Keating, Michael J., Gandhi, Varsha
Publicado 2016

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells

por Modi, Prexy, Balakrishnan, Kumudha, Yang, Qingshan, Wierda, William G., Keating, Michael J., Gandhi, Varsha
Publicado 2017

The TKI Era in Chronic Leukemias

por De Novellis, Danilo, Cacace, Fabiana, Caprioli, Valeria, Wierda, William G., Mahadeo, Kris M., Tambaro, Francesco Paolo
Publicado 2021

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia

por Yi, Xue, Jain, Nitin, Iles, LaKesla R., Ayres, Mary L., Wierda, William G., Gandhi, Varsha
Publicado 2022

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells

por Cervantes-Gomez, Fabiola, Stellrecht, Christine M., Ayres, Mary L., Keating, Michael J., Wierda, William G., Gandhi, Varsha
Publicado 2019

2211. Impact of Early Fiberoptic Bronchoscopy on Microbiological Diagnostic Rate and Clinical Outcomes of Pneumonia in Acute Leukemia Patients

por Sakurai, Aki, Bala-Hampton, Justin E, Mulanovich, Victor E, Wierda, William G, Cortes, Jorge E, Adachi, Javier
Publicado 2019

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

por Aslan, Burcu, Hubner, Stefan Edward, Fox, Judith A., Taverna, Pietro, Wierda, William G., Kornblau, Steven M., Gandhi, Varsha
Publicado 2021

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

por Chen, Rong, Chen, Yuling, Xiong, Ping, Zheleva, Daniella, Blake, David, Keating, Michael J., Wierda, William G., Plunkett, William
Publicado 2022

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells

por Vangapandu, Hima V., Alston, Brandon, Morse, Joshua, Ayres, Mary L., Wierda, William G., Keating, Michael J., Marszalek, Joseph R., Gandhi, Varsha
Publicado 2018

1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)

por Frei, Michael, Aitken, Samuel L, Aitken, Samuel L, Jain, Nitin, Thompson, Philip, Wierda, William G, Kontoyiannis, Dimitrios P, DiPippo, Adam
Publicado 2019

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

por O’Brien, Susan M., Brown, Jennifer R., Byrd, John C., Furman, Richard R., Ghia, Paolo, Sharman, Jeff P., Wierda, William G.
Publicado 2021

The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells()()

por Vangapandu, Hima V., Ayres, Mary L., Bristow, Christopher A., Wierda, William G., Keating, Michael J., Balakrishnan, Kumudha, Stellrecht, Christine M., Gandhi, Varsha
Publicado 2017

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

por Sharman, Jeffrey P., Biondo, Juliana M. L., Boyer, Michelle, Fischer, Kirsten, Hallek, Michael, Jiang, Dingfeng, Kater, Arnon P., Porro Lurà, Michele, Wierda, William G.
Publicado 2022

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

por Aslan, Burcu, Kismali, Gorkem, Iles, Lakesla R., Manyam, Ganiraju C., Ayres, Mary L., Chen, Lisa S., Gagea, Mihai, Bertilaccio, Maria Teresa Sabrina, Wierda, William G., Gandhi, Varsha
Publicado 2022

Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19

por Esposito, Carla L., Van Roosbroeck, Katrien, Santamaria, Gianluca, Rotoli, Deborah, Sandomenico, Annamaria, Wierda, William G., Ferrajoli, Alessandra, Ruvo, Menotti, Calin, George A., de Franciscis, Vittorio, Catuogno, Silvia
Publicado 2021

The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

por Chen, Rong, Tsai, Jennifer, Thompson, Philip A., Chen, Yuling, Xiong, Ping, Liu, Chaomei, Burrows, Francis, Sivina, Mariela, Burger, Jan A., Keating, Michael J., Wierda, William G., Plunkett, William
Publicado 2021

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PH...

por Ghia, Paolo, Allan, John, Siddiqi, Tanya, Wierda, William G., Tam, Constantine, Moreno, Carol, Tedeschi, Alessandra, Szafer-Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, Jim, Szoke, Anita, Barr, Paul M.
Publicado 2023